Jamieson is delighted to announce it has advised the management team of Synlab on the company’s IPO on the Frankfurt Stock Exchange.
SYNLAB offers a full range of medical diagnostic services for practising doctors, clinics and patients. The SYNLAB Group is the uncontested leader on the European market for human medicine laboratory services. SYNLAB particularly focuses on the implementation of innovative laboratory medicine methods and on networking specialist diagnostic competences (SYNLAB Centres of Excellence).
Synlab’s revenue in 2020 was €2.6 billion.
Stuart Coventry and Daniel Meschaninov advised Mathieu Floreani (CEO), Sami Badarani (CFO) and the management team on commercial terms relating to their shareholding at IPO and their economic arrangements going forward.
